Fanapt
Total Payments
$1.5M
Transactions
29,193
Doctors
5,766
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.1M | 9,915 | 3,188 |
| 2018 | $154,869 | 8,190 | 2,882 |
| 2017 | $218,210 | 11,088 | 3,663 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $972,175 | 33 | 66.0% |
| Food and Beverage | $471,254 | 28,190 | 32.0% |
| Consulting Fee | $15,688 | 6 | 1.1% |
| Education | $6,113 | 953 | 0.4% |
| Travel and Lodging | $4,268 | 10 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500 | 1 | 0.2% |
Payments by Type
Research
$972,175
33 transactions
General
$499,823
29,160 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-label, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long Acting Injectable in Subjects with Schizophrenia | Vanda Pharmaceuticals Inc. | $685,829 | 1 |
| A safety/tolerance study to evaluate a new titration scheme in patients with bipolar disorder or schizophrenia | Vanda Pharmaceuticals Inc. | $133,225 | 0 |
| Study of Cytochrome P450 2D6 (CYP2D6) Patients with Schizophrenia | Vanda Pharmaceuticals Inc. | $75,541 | 0 |
| A safety/tolerance study to evaluate a new titration scheme in patients with bipolar disorder or schizophrenia. | Vanda Pharmaceuticals Inc. | $49,550 | 0 |
| Iloperidone in Mixed States of Bipolar Disorder | Vanda Pharmaceuticals Inc. | $28,030 | 0 |
Top Doctors Receiving Payments for Fanapt — Page 231
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Specialist | Gulfport, MS | $10.60 | 1 |
| , MD | Psychiatry | Waco, TX | $10.58 | 1 |
| , M.D | Psychosomatic Medicine | Boston, MA | $10.55 | 1 |
| , M.D | Psychiatry | Columbus, OH | $10.55 | 1 |
| , MD | Psychiatry | Bethlehem, PA | $10.55 | 1 |
| Bhaskar Nayak | Psychiatry | Commack, NY | $10.54 | 1 |
| , M.D | Sports Medicine | Munfordville, KY | $10.54 | 1 |
| , D.O | Psychiatry | Barberton, OH | $10.50 | 1 |
| , MD | Psychiatry | Lincoln, NE | $10.47 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Little Rock, AR | $10.45 | 1 |
| , M.D | Psychiatry | Duluth, MN | $10.43 | 1 |
| , M.D | Psychiatry | Garden City, NY | $10.43 | 1 |
| , M.D | Psychiatry | Xenia, OH | $10.43 | 1 |
| , MD | Family Medicine | Wake Forest, NC | $10.43 | 1 |
| , M.D | Psychiatry | Clinton Twp, MI | $10.40 | 1 |
| , MD | Physical Medicine & Rehabilitation | Melbourne, FL | $10.34 | 1 |
| Natarajan Laks | — | Festus, MO | $10.33 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 5,766
- Transactions 29,193
About Fanapt
Fanapt is a drug associated with $1.5M in payments to 5,766 healthcare providers, recorded across 29,193 transactions in the CMS Open Payments database. The primary manufacturer is Vanda Pharmaceuticals Inc..
Payment data is available from 2017 to 2019. In 2019, $1.1M was paid across 9,915 transactions to 3,188 doctors.
The most common payment nature for Fanapt is "Unspecified" ($972,175, 66.0% of total).
Fanapt is associated with 5 research studies, including "An Open-label, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long Acting Injectable in Subjects with Schizophrenia" ($685,829).